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Objective: The aim of the present study was to investigate which 
of 13 radiographical knee features of the Altman grading scale for 
knee osteoarthritis [joint space narrowing for the medial com- 
partment (JSNM) and the lateral tibial compartment (JSNL), mar- 
ginal osteophytes formation at the medial femoral condyle (OFM), 
medial tibial plateau (OTM), lateral femoral condyle (OFL), and lat- 
eral tibial plateau (OTL), subchondral sclerosis at the medial 
femoral condyle (SFM), medial tibial plateau (STM), lateral femoral 
condyle (SFL) and lateral tibial plateau (STL), valgus or varus 
malalignment (MAL), bony attrition of the medial tibial plateau 
(ART) and the presence or absence of hypertrophy of the tibial 
spinous insertions of the cruciate ligaments (HYP)] was the best 
predictor of joint space narrowing at the medial femoro-tibial 
compartment, over a period of 3 years. 
Method: Data were derived from a cohort of 106 individuals cor- 
responding to the placebo arm of a 3-year double-blind placebo 
controled trial. We allocated to each X-ray a score from 0 to 3, 
depending upon the severity of the 13 radiographic features. We 
also measured, at baseline and after 3 years, the mean joint 
space width (JSVV) by digital image analysis with a validated com- 
puterized algorithm and the minimal JSW with a graduated mag- 
nifying lens. 
Results: STM was the only parameter significantly correlated 
with 3-year changes in mean JSW (r = 0.29, p = 0.02) and mini- 
mal JSW (r=0.23, p=0.04). We found a statistically significant dif- 
ference (p=0.04) between patients with a STM of 0 or 1 who had 
a mean joint space narrowing of 5.1 (SD: 18.0) % compared with 
patients with a STM of 2 or 3 who had a gain of 9.0 (25.8) % over 
3 years. The difference was also significant (p=0.01) when con- 
sidering 3-year changes in the minimal JSW, with a change of - 
10.7 (24.7) % and + 16.0 (53.9) % for patients with a STM of 0 or 
1 and 2 or 3, respectively. 
Conclusion: We conclude that assessment of tibial sclerosis 
could predict the 3-years knee radiological progression. 
Nevertheless, a precise measurement, may be with a DXA, could 
probably be useful for a better assessment of tibial sclerosis. 
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Background. Preliminary studies have shown that dual energy X 
ray absorptiometry (DXA) can produce images of sufficient quali- 
ty for a precise measurement of density of the subchondral bone. 
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Objective. The aim of our study was to investigate the relation- 
ship between subchondral tibial bone mineral density (BMD) and 
joint space width at the medial femoro-tibial knee joint. 
Method: In all, 67 patients, from both genders, with knee OA 
diagnosed according to the American College of Rheumatology 
criteria, were included in the study. Radiographic Schuss views 
were taken and mean joint space width (JSW) measurement at 
the medial femoro-tibial joint was performed with a digitized 
image analysis. BMD of the subchondral tibial bone was 
assessed by dual energy X ray absorptiometry (DXA) with a high- 
ly reproducible technique (CV=1.5 %). 
Results: The mean (SD) age of the patients was 65.2 (8.6) years, 
with a body mass index of 28.5 (5.9) kg/m 2. Mean JSW was 4.4 
(1.8) mm. Mean BMD of the subchondral bone was 0.889 (0.22) 
g/cm L. There was a significant negative correlation between sub- 
chondral BMD and mean JSW (r = -0.31, p <0.001). When divid- 
ing our population into quartiles of BMD, patients in the first quar- 
tile (BMD <0.733) have mean JSW of 5.05 (1.57) mm compared 
with 3.70 (2.18) mm for patients in the fourth quartile (BMD > 
0.999). Difference between the two populations was statistically 
significant (p = 0.05). 
Conclusion: BMD is highly correlated with JSW and could be 
useful for the diagnosis of knee OA. However, longitudinal stud- 
ies must be done in order to assess the interest of measuring 
subchondral bone density for the monitoring of joint space nar- 
rowing in knee OA. 
PAl7 
PAIN RELIEF IN OSTEOARTHRITlS (OA) OF THE KNEE 
JP Case, JA Block 
Rush Medical College, Chicago, USA 
The role of the pure analgesic, acetaminophen (A), relative to that 
of non-steroidal anti-inflammatory drugs (NSAIDs) in the treat- 
ment of QA remains controversial. The few published studies are 
conflicting, and in its 2000 update, the American College of 
Rheumatology recommended initial treatment with A in OA of the 
hip or knee. 
Methods: A 12-week randomized, double-blind, placebo (P)con- 
trolled trial of diclofenac (D) (75 mg bid) vs. A (1000 mg qid) in 
medial knee OA. Inclusions: radiographic QA (modified 
KellgrenLawrence grade ~1 and medial joint involvement) and 
symptomatic OA: (1) pro-enrollment ambulatory pain (VAS of ~30 
in WOMAC question 1 or moderate pain by five-point Liked) or (2) 
increased pain during 2-week washout of any pre-existing med- 
ications (VAS change of ~10 or Likert change of ~1). 82 subjects 
were randomized. Analysis: By WOMAC and Lequesne after 
washout (week O) and at 2 and 12 weeks of treatment with D (25 
subjects), A (29 subjects), or P (28 subjects). 
Results: 61 subjects completed the study (20/22/19 in D/AJP 
groups). Groupwise dropouts by 2 or 12 weeks were as follows: 
By 2 weeks: 2/1/2. Cumulatively by 12 weeks: 5/8/9. Reasons for 
dropout were insufficient pain relief (2/5/3), upper gastrointestinal 
side effects (1/2/0), and other reasons (2/1/6). Results of the 
WOMAC pain section (WOp) and WOMAC total (WOt) are pre- 
sented (Table). The improvement in WOp and WOt from D was 
significantly greater than that from A or P at week 2 (p~0.003), 
though the difference did not reach statistical significance at 
week 12. A was never significantly different from P. Lequesne 
results were comparable to WOMAC. 
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Conclusions: In subjects with radiographic knee OA of defined 
pain severity, significant relief is effected by D at 2 & 12 weeks 
according to two validated, widely-used OA instruments, where- 
as A is not signficantly different han P. 
Group wo Week 0 Week 2 % better p W e e k 
12 % better p 
D WOp 200=102 140==105 30 0.0001 146¢101 27 0,002 
WOt 97±50 706=536 27 0,001 719=516 26 0.0001 
A WOp 211±86 206±101 2 0,671 187±122 11 0.134 
WOt 964±375 906¢-453 0 0.919 889=529 8 0,191 
P WOp 199±111 197±119 1 0,878 183¢123 8 0,420 
WOt 994±520 947=516 5 0.221 878±521 12 0.085 
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Aim: Etoricoxib, a highly selective cyclooxygenase-2 (COX-2) 
inhibitor, has demonstrated efficacy in OA and RA. We compared 
the efficacy of etoricoxib, naproxen, and placebo on QoL 
(Medical Outcomes Trust SF-36) in OA patients in the 12-week 
portion of 2 phase III trials. 
Methods: Replicate, multicenter, randomized, parallel-group, 
double-blind studies enrolled a total of 997 patients with OA of 
the knee or hip who had worsening symptoms (flare) upon dis- 
continuation of OA therapy. Baseline measures were obtained at 
the flare visit, prior to randomization to etoricoxib 60 mg once 
daily (N=446), naproxen 500 mg twice daily (N=439), or placebo 
(N=112). Clinical efficacy data were collected at 2, 4, 8, and 12 
weeks. Analyses were done on all patients randomized. The SF- 
36 domain and Physical Component Summary (PCS) and Mental 
Component Summary (MCS) scores were calculated using estab- 
lished methods (on a 0-100 scale; higher scores are better). Mean 
scores change from baseline to week-12, adjusted for baseline 
value and primary study joint (knee vs hip), were compared 
across treatments. 
Results: Etoricoxib was superior to placebo and comparable 
with naproxen on all three primary efficacy measures (WOMAC 
pain and physical function subscales, and patient global assess- 
ment of disease status), and was well tolerated over 12 weeks. 
For the QoL measure, mean baseline scores for the etoricoxib 
and placebo arms were similar for each domain, the PCS, and 
MCS. The difference (p-value) in the domain scores [mean 
change between etoricoxib and placebo] were: physical function- 
ing 7.7 (<0.001); role physical 12.5 (<0.001); pain 9.7 (<0.001); 
general health perceptions 4.4 (<0.001); mental health 2.5 (0.08); 
role emotional 13.1 (<0.001); social functioning 7.6 (<0.001); vital- 
ity 6.6 (<0.001). For the PCS and MCS, the difference between 
etoricoxib and placebo was 3.6 (<0.001) and 2.3 (0.008), respec- 
tively. Similar results were found comparing naproxen to placebo. 
Differences between etoricoxib and naproxen were slight and not 
statistically different on any of the SF-36 scores. 
Conclusion: In this study, patients with OA of the hip or knee 
treated with etoricoxib 60 mg once daily for 12 weeks had statis- 
tically significantly greater improvement in 7 of 8 SF-36 domain 
scores and in both the Physical and Mental Component Summary 
scores compared with placebo. These improvements are consis- 
tent with the OA efficacy results observed in this study. 
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Osteoarthritis (OA) in real life settings is often difficult to study, 
especially in France where no reliable database exists to explore 
prescription habits of physicians. 
Methods: In 2000, a nation-wide survey in more than 5000 physi- 
cians, either general practitioners (90.3%) or rheumatologists 
(9.7%), representative of the French medical demography, was 
conducted. Each recruited the first two patients consulting for 
hip, knee or hand OA after the onset of the survey. 
Results: Medical information was available for 10412 patients, 
whose OA was diagnosed on both clinical and radiological find- 
ings in 84.5%. Their mean age was 66.2 ± 10.2 years with a sex 




Anti-OA agents* 89.8% 
Topical NSIAD 60.2% 
Steroid joint injection in past 19.7% 
year 
Hyaluronic acid injection in 1.5% 
past year 
Physiotherapy 28.4% 




71.1 % 28.9% 
65.4% 34.6% 
(Mean number t .7 ±0.9) 
Massage: 77.7% 
Muscle strengthening:50.6% 
Both analgesics and NSAIDs were prescribed as needed vs daily 
in the majority of patients (67.4 and 70.4%). There was no major 
difference in the use of these medications according to the fre- 
quency of pain, the type of symptoms and the site of OA. 
Moreover, 28.8% of OA patients reported use of complementary 
and alternative medicine. The most commonly used were 
mesotherapy 48.4% (subcutaneous injections of medication), 
acupuncture 23.4%, herbal remedies 15.6%, homeopathy 
14.8%. 
Conclusion: This study provides a representative overview of the 
prescription habits of French physicians for OA. It emphasizes the 
great frequency of therapeutic ombinations, with minor differ- 
ences according to the symptoms or the site of OA. Local thera- 
py, especially steroid injections, and physiotherapy were also 
commonly used. 
